CoChat
Sign Up
Cited by 85

Stool DNA Testing for Screening Detection of Colorectal Neoplasia in Alaska Native People

Redwood, Diana G., Asay, Elvin D., Blake, Ian D., Sacco, Pamela E., Christensen, Claudia M., Sacco, Frank D., Tiesinga, James J., Devens, Mary E. +7 more·2016·Mayo Clinic Proceedings
DOI 10.1016/j.mayocp.2015.10.008
Open this paper in CoChat — free account

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.mayocp.2015.10.008

Cites

3 of 3 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Observed detection rates for advanced precancers were lower than those reported for FIT with advanced conventional adenomas and similar to those reported with SSAs.

    “observed detection rates for these advanced precancers were lower than those reported for FIT with advanced conventional adenomas [9, 11, 26] and similar to those reported with SSAs [9, 11, 13].”

    From Novel Approach to Fecal Occult Blood Testing by Assay of Erythrocyte-Specific microRNA Markers (2017) · cites this paper as [11]

  • A multi-target stool test comprising DNA markers and FIT has been approved by FDA for CRC screening, incorporated into guidelines, and become available.

    “A multi-target stool test, comprising a panel of DNA markers and FIT [9–11], has been approved by the Food and Drug Administration (FDA) for CRC screening, been incorporated into CRC screening guidelines by the American Cancer Society and United States Preventive Services Task Force [14, 15], and become available to patients.”

    From Novel Approach to Fecal Occult Blood Testing by Assay of Erythrocyte-Specific microRNA Markers (2017) · cites this paper as [11]

  • Combining FIT with assay of exfoliated molecular markers in stool expands sensitivity of stool testing for colorectal neoplasia.

    “Combining a FIT application with assay of exfoliated molecular markers in stool has proven to be a rational and effective approach to further expand the sensitivity of stool testing for detection of colorectal neoplasia [8–11].”

    From Novel Approach to Fecal Occult Blood Testing by Assay of Erythrocyte-Specific microRNA Markers (2017) · cites this paper as [11]

  • The FDA-approved multi-target stool DNA test combines FIT and a DNA marker panel.

    “The FDA-approved multi-target stool DNA test combines FIT and a DNA marker panel [9, 11].”

    From Novel Approach to Fecal Occult Blood Testing by Assay of Erythrocyte-Specific microRNA Markers (2017) · cites this paper as [11]

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Research works printed but not linked: 32

  1. [1]1. Kelly, J.J. ∙ Alberts, S.R. ∙ Sacco, F. ... Colorectal cancer in Alaska Native people, 2005-2009 Gastrointest Cancer Res. 2012; 5(5):149-154 PubMed Google Scholar
  2. [5]5. Zauber, A.G. ∙ Lansdorp-Vogelaar, I. Changes in risk factors and increases in screening contribute to the decline in colorectal cancer mortality, 1975 to 2000 Gastroenterology. 2010; 139(2):698 Full Text Full Text (PDF) Scopus (10) PubMed Google Scholar
  3. [7]7. Levin, B. ∙ Lieberman, D.A. ∙ McFarland, B. ..., American Cancer Society Colorectal Cancer Advisory Group; US Multi-Society Task Force; American College of Radiology Colon Cancer Committee Screening and surveillance for the early detection of colorectal cancer and adenomatous polyps, 2008: a joint guideline from the American Cancer Society, the US Multi-Society Task Force on Colorectal Cancer, and the American College of Radiology Gastroenterology. 2008; 134(5):1570-1595 Full Text Full Text (PDF) Scopus (1785) PubMed Google Scholar
  4. [9]9. Redwood, D. ∙ Joseph, D.A. ∙ Christensen, C. ... Development of a flexible sigmoidoscopy training program for rural nurse practitioners and physician assistants to increase colorectal cancer screening among Alaska Native people J Health Care Poor Underserved. 2009; 20(4):1041-1048 Crossref Scopus (15) PubMed Google Scholar
  5. [10]10. Redwood, D. ∙ Provost, E. ∙ Perdue, D. ... The last frontier: innovative efforts to reduce colorectal cancer disparities among the remote Alaska Native population Gastrointest Endosc. 2012; 75(3):474-480 Full Text Full Text (PDF) Scopus (38) PubMed Google Scholar
  6. [11]11. Atkin, W.S. ∙ Edwards, R. ∙ Kralj-Hans, I. ... UK Flexible Sigmoidoscopy Trial Investigators. Once-only flexible sigmoidoscopy screening in prevention of colorectal cancer: a multicentre randomised controlled trial Lancet. 2010; 375(9726):1624-1633 Full Text Full Text (PDF) Scopus (1420) PubMed Google Scholar
  7. [12]12. Schoen, R.E. ∙ Pinsky, P.F. ∙ Weissfeld, J.L. ..., PLCO Project Team Colorectal-cancer incidence and mortality with screening flexible sigmoidoscopy N Engl J Med. 2012; 366(25):2345-2357 Crossref Scopus (855) PubMed Google Scholar
  8. [13]13. Baxter, N.N. ∙ Goldwasser, M.A. ∙ Paszat, L.F. ... Association of colonoscopy and death from colorectal cancer Ann Intern Med. 2009; 150(1):1-8 Crossref Scopus (1117) PubMed Google Scholar
  9. [14]14. Brenner, H. ∙ Hoffmeister, M. ∙ Arndt, V. ... Protection from right- and left-sided colorectal neoplasms after colonoscopy: population-based study J Natl Cancer Inst. 2010; 102(2):89-95 Crossref Scopus (486) PubMed Google Scholar
  10. [16]16. Morikawa, T. ∙ Kato, J. ∙ Yamaji, Y. ... A comparison of the immunochemical fecal occult blood test and total colonoscopy in the asymptomatic population Gastroenterology. 2005; 129(2):422-428 Full Text Full Text (PDF) PubMed Google Scholar
  11. [17]17. Ahlquist, D.A. ∙ Wieand, H.S. ∙ Moertel, C.G. ... Accuracy of fecal occult blood screening for colorectal neoplasia: a prospective study using Hemoccult and HemoQuant tests JAMA. 1993; 269(10):1262-1267 Crossref Scopus (314) PubMed Google Scholar
  12. [18]18. Yip, R. ∙ Limburg, P.J. ∙ Ahlquist, D.A. ... Pervasive occult gastrointestinal bleeding in an Alaska native population with prevalent iron deficiency: role of Helicobacter pylori gastritis JAMA. 1997; 277(14):1135-1139 Crossref PubMed Google Scholar
  13. [19]19. Redwood, D. ∙ Provost, E. ∙ Asay, E. ... Comparison of fecal occult blood tests for colorectal cancer screening in an Alaska Native population with high prevalence of Helicobacter pylori infection, 2008-2012 Prev Chronic Dis. 2014; 11:E56 Crossref Scopus (18) PubMed Google Scholar
  14. [20]20. Ahlquist, D.A. ∙ Sargent, D.J. ∙ Loprinzi, C.L. ... Stool DNA and occult blood testing for screen detection of colorectal neoplasia Ann Intern Med. 2008; 149(7):441-450 Crossref Scopus (255) PubMed Google Scholar
  15. [21]21. Imperiale, T.F. ∙ Ransohoff, D.F. ∙ Itzkowitz, S.H. ... Colorectal Cancer Study Group. Fecal DNA versus fecal occult blood for colorectal-cancer screening in an average-risk population N Engl J Med. 2004; 351(26):2704-2714 Crossref Scopus (723) PubMed Google Scholar
  16. [22]22. Heigh, R.I. ∙ Yab, T.C. ∙ Taylor, W.R. ... Detection of colorectal serrated polyps by stool DNA testing: comparison with fecal immunochemical testing for occult blood (FIT) PLoS One. 2014; 9(1):e85659 Crossref Scopus (61) PubMed Google Scholar
  17. [23]23. Berger, B.M. ∙ Ahlquist, D.A. Stool DNA screening for colorectal neoplasia: biological and technical basis for high detection rates Pathology. 2012; 44(2):80-88 Crossref Scopus (68) PubMed Google Scholar
  18. [24]24. Ahlquist, D.A. Multi-target stool DNA test: a new high bar for noninvasive screening Dig Dis Sci. 2015; 60(3):623-633 Crossref Scopus (54) PubMed Google Scholar
  19. [26]26. Lidgard, G.P. ∙ Domanico, M.J. ∙ Bruinsma, J.J. ... Clinical performance of an automated stool DNA assay for detection of colorectal neoplasia Clin Gastroenterol Hepatol. 2013; 11(10):1313-1318 Full Text Full Text (PDF) Scopus (119) PubMed Google Scholar
  20. [27]27. Ahlquist, D.A. ∙ Zou, H. ∙ Domanico, M. ... Next-generation stool DNA test accurately detects colorectal cancer and large adenomas Gastroenterology. 2012; 142(2):248-256 Full Text Full Text (PDF) Scopus (262) PubMed Google Scholar
  21. [28]28. Rex, D.K. ∙ Ahnen, D.J. ∙ Baron, J.A. ... Serrated lesions of the colorectum: review and recommendations from an expert panel Am J Gastroenterol. 2012; 107(9):1315-1329 Crossref Scopus (909) PubMed Google Scholar
  22. [29]29. Moskowitz, C.S. ∙ Pepe, M.S. Comparing the predictive values of diagnostic tests: sample size and analysis for paired study designs Clin Trials. 2006; 3(3):272-279 Crossref Scopus (131) PubMed Google Scholar
  23. [30]30. Bressler, B. ∙ Paszat, L.F. ∙ Vinden, C. ... Colonoscopic miss rates for right-sided colon cancer: a population-based analysis Gastroenterology. 2004; 127(2):452-456 Full Text Full Text (PDF) Scopus (291) PubMed Google Scholar
  24. [31]31. Patel, S.G. ∙ Ahnen, D.J. Prevention of interval colorectal cancers: what every clinician needs to know Clin Gastroenterol Hepatol. 2014; 12(1):7-15 Full Text Full Text (PDF) Scopus (48) PubMed Google Scholar
  25. [32]32. Cooper, G.S. ∙ Xu, F. ∙ Barnholtz Sloan, J.S. ... Prevalence and predictors of interval colorectal cancers in Medicare beneficiaries Cancer. 2012; 118(12):3044-3052 Crossref Scopus (194) PubMed Google Scholar
  26. [33]33. Singh, H. ∙ Nugent, Z. ∙ Mahmud, S.M. ... Predictors of colorectal cancer after negative colonoscopy: a population-based study Am J Gastroenterol. 2010; 105(3):663-673 Crossref Scopus (163) PubMed Google Scholar
  27. [34]34. Samadder, N.J. ∙ Curtin, K. ∙ Tuohy, T.M. ... Characteristics of missed or interval colorectal cancer and patient survival: a population-based study Gastroenterology. 2014; 146(4):950-960 Full Text Full Text (PDF) Scopus (234) PubMed Google Scholar
  28. [35]35. Pickhardt, P.J. ∙ Hain, K.S. ∙ Kim, D.H. ... Low rates of cancer or high-grade dysplasia in colorectal polyps collected from computed tomography colonography screening Clin Gastroenterol Hepatol. 2010; 8(7):610-615 Full Text Full Text (PDF) Scopus (62) PubMed Google Scholar
  29. [36]36. Muto, T. ∙ Bussey, H.J. ∙ Morson, B.C. The evolution of cancer of the colon and rectum Cancer. 1975; 36(6):2251-2270 Crossref Scopus (1980) PubMed Google Scholar
  30. [37]37. Pickhardt, P.J. The natural history of colorectal polyps and masses: rediscovered truths from the barium enema era AJR Am J Roentgenol. 2007; 188(3):619-621 Crossref Scopus (23) PubMed Google Scholar
  31. [38]38. Vogelstein, B. ∙ Fearon, E.R. ∙ Hamilton, S.R. ... Genetic alterations during colorectal-tumor development N Engl J Med. 1988; 319(9):525-532 Crossref Scopus (6250) PubMed Google Scholar
  32. [39]39. Stryker, S.J. ∙ Wolff, B.G. ∙ Culp, C.E. ... Natural history of untreated colonic polyps Gastroenterology. 1987; 93(5):1009-1013

Cited by

Sorted by citations

Authors
Redwood, D. G., Asay, E. D., Blake, I. D., Sacco, P. E., Christensen, C. M., Sacco, F. D., Tiesinga, J. J., Devens, M. E., Alberts, S. R., Mahoney, D. W., Yab, T. C., Foote, P. H., Smyrk, T. C., Provost, E. M., & Ahlquist, D. A.
Venue
Mayo Clinic Proceedings
Publisher
Elsevier BV
Published
2016-01
Volume
91
Issue
1
Pages
61-70
ISSN
0025-6196
DOI
10.1016/j.mayocp.2015.10.008
Cited by
85
References
3
Language
en
Licence

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review